Number of qualified clients: CDEC reviewed the uncertainty in the amount of sufferers with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical industry experts consulted by CADTH indicated that some people who will be categorised as obtaining gentle or moderate sickness can have a intense bleeding p